Andrea Marchetti
About
Andrea Marchetti is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery.
According to data from OpenAlex, Andrea Marchetti has authored 48 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Pulmonary and Respiratory Medicine, 28 papers in Oncology and 16 papers in Surgery. Recurrent topics in Andrea Marchetti's work include Cancer Immunotherapy and Biomarkers (22 papers), Renal cell carcinoma treatment (19 papers) and Bladder and Urothelial Cancer Treatments (13 papers). Andrea Marchetti is often cited by papers focused on Cancer Immunotherapy and Biomarkers (22 papers), Renal cell carcinoma treatment (19 papers) and Bladder and Urothelial Cancer Treatments (13 papers). Andrea Marchetti collaborates with scholars based in Italy, United States and Spain. Andrea Marchetti's co-authors include Francesco Massari, Matteo Rosellini, Veronica Mollica, Alessandro Rizzo, Matteo Santoni, Elisa Tassinari, Nicola Battelli, Luca Faloppi, Valentina Tateo and Andrea Ardizzoni and has published in prestigious journals such as International Journal of Molecular Sciences, European Urology and European Journal of Cancer.
In The Last Decade
Andrea Marchetti
45 papers receiving 1.1k citations
Hit Papers
Peers
Andrea Marchetti
Matteo Rosellini Italy
Jiuda Zhao China
Xianshu Gao China
Alessia Mennitto Italy
Pallavi S. Mishra‐Kalyani United States
Guoshuang Shen China
Antonella Palazzo Italy
Edgardo S. Santos United States
Shuqiang Yuan China
Zhihuang Hu China
Citations per year, relative to Andrea Marchetti Andrea Marchetti (= 1×)
peers
Matteo Rosellini
Countries citing papers authored by Andrea Marchetti
Since
Specialization
Citations
This map shows the geographic impact of Andrea Marchetti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrea Marchetti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrea Marchetti more than expected).
Fields of papers citing papers by Andrea Marchetti
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Andrea Marchetti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrea Marchetti. The network helps show where Andrea Marchetti may publish in the future.
Co-authorship network of co-authors of Andrea Marchetti
This figure shows the co-authorship network connecting the top 25 collaborators of Andrea Marchetti. A scholar is included among the top collaborators of Andrea Marchetti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrea Marchetti. Andrea Marchetti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Ricci, Costantino, Francesca Ambrosi, Francesco Vasuri, et al.. (2025). Immunohistochemical expression of Nectin-4 and potential implications for enfortumab vedotin therapy in germ cell tumors of the testis: a preliminary study. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 488(3). 499–510.
2.
Rosellini, Matteo, Veronica Mollica, Andrea Marchetti, et al.. (2025). Insights into the impact of chromosome 3p mutations in advanced renal cell carcinoma treated with immune-based combinations or targeted therapy: A single-center experience. Pathology - Research and Practice. 270. 155964–155964.
3.
Mollica, Veronica, Andrea Marchetti, Cristina Nanni, et al.. (2024). A prospective study on the early evaluation of response to androgen receptor-targeted agents with 11C-Choline, 68Ga-PSMA, and 18F-FACBC PET in metastatic castration-resistant prostate cancer: a single-center experience. ESMO Open. 9(5). 103448–103448.
4.
Casadio, Chiara, Matteo Rosellini, Andrea Marchetti, et al.. (2024). Novel Immune Checkpoint Inhibitor Targets in Advanced or Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives. Journal of Clinical Medicine. 13(19). 5738–5738.
5.
Tassinari, Elisa, Andrea Marchetti, Matteo Rosellini, et al.. (2024). State of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changes. Human Vaccines & Immunotherapeutics. 21(1). 2440165–2440165.
6.
Mollica, Veronica, Alessandro Rizzo, Andrea Marchetti, et al.. (2023). The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study. Clinical and Experimental Medicine. 23(8). 5039–5049.
7.
Rizzo, Alessandro, Veronica Mollica, Valentina Tateo, et al.. (2023). Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study. Cancer Immunology Immunotherapy. 72(6). 1381–1394.
8.
Santoni, Matteo, Alessandro Rizzo, Jakub Kucharz, et al.. (2023). Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis. Cancer Immunology Immunotherapy. 72(6). 1365–1379.
9.
Marchetti, Andrea, Matteo Rosellini, Elisa Tassinari, et al.. (2022). PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What’s Now, What’s New, and What’s Coming?. Cancers. 14(4). 907–907.
10.
Rizzo, Alessandro, Veronica Mollica, Andrea Marchetti, et al.. (2022). Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study. Cancers. 14(17). 4142–4142.
11.
Mollica, Veronica, Elisa Tassinari, Andrea Marchetti, et al.. (2022). Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw. Current Oncology. 29(3). 1709–1722.
12.
Rosellini, Matteo, Andrea Marchetti, Veronica Mollica, et al.. (2022). Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma. Nature Reviews Urology. 20(3). 133–157.
13.
Mollica, Veronica, Dario de Biase, Francesca Giunchi, et al.. (2022). A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy.. Pathology - Research and Practice. 236. 153983–153983.
14.
Mollica, Veronica, Andrea Marchetti, Matteo Rosellini, et al.. (2021). An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKT. International Journal of Molecular Sciences. 22(24). 13519–13519.
15.
Mollica, Veronica, Alessandro Rizzo, Matteo Rosellini, et al.. (2021). Bone Targeting Agents in Patients with Metastatic Prostate Cancer: State of the Art. Cancers. 13(3). 546–546.
16.
Marchetti, Andrea, Matteo Rosellini, Veronica Mollica, et al.. (2021). The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What’s the Story Morning Glory?. International Journal of Molecular Sciences. 22(12). 6237–6237.
17.
Rizzo, Alessandro, Veronica Mollica, Matteo Rosellini, et al.. (2021). Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials. Pathology - Research and Practice. 222. 153440–153440.
18.
Mollica, Veronica, Matteo Santoni, Marc Matrana, et al.. (2021). Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma. Targeted Oncology. 17(1). 61–68.
19.
Massari, Francesco, Alessandro Rizzo, Veronica Mollica, et al.. (2021). Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials. European Journal of Cancer. 154. 120–127.
20.
Rizzo, Alessandro, Veronica Mollica, Matteo Santoni, et al.. (2021). Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials. European Urology Focus. 8(2). 514–521.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Matteo Rosellini Breakdown of academic impact, for papers by Jiuda Zhao Breakdown of academic impact, for papers by Xianshu Gao Breakdown of academic impact, for papers by Alessia Mennitto Breakdown of academic impact, for papers by Pallavi S. Mishra‐Kalyani Breakdown of academic impact, for papers by Guoshuang Shen Breakdown of academic impact, for papers by Antonella Palazzo Breakdown of academic impact, for papers by Edgardo S. Santos Breakdown of academic impact, for papers by Shuqiang Yuan Breakdown of academic impact, for papers by Zhihuang Hu